Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

Yu Qiao(Harbin Medical University), Yao Wang(Anhui Medical University), Peihong Wu(Hebei Medical University), Lili Liu(Peking University), Li Zhang(Fourth Hospital of Changsha), Yunbo Zhao(University of Science and Technology of China), Huan Xi(Beijing Hospital), Dongge Liu(Beijing Hospital), Jihong Yang(Zhejiang Lab), Huan Chen(Zhejiang Chinese Medical University), Jing Jia, Xiaoguang Li(Beijing Hospital), Wenchao Wang(Nanjing Forestry University), Jie Ma(Tianjin University of Traditional Chinese Medicine)
BMC Cancer
February 21, 2018
10.1186/s12885-018-3996-3
Cited by 24

Related Papers

A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Polystyrene microplastics induce microbiota dysbiosis and inflammation in the gut of adult zebrafish
|Environmental Pollution|2018|824
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Platelet Glycoprotein Ibα Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18)
|The Journal of Experimental Medicine|2000|582
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334